• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Arixtra (fondaparinux sodium) injections

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)  

 

 

September 2013

Summary View

4 CONTRAINDICATIONS

  • History of serious hypersensitivity reaction (e.g., angioedema, anaphylactoid/anaphylactic reactions) to ARIXTRA

6 ADVERSE REACTIONS

6.5 Postmarketing Experience
  • the occurrence of serious allergic reactions (including angioedema and anaphylactoid/anaphylactic reactions) 

 

March 2010

Summary View

USE IN SPECIFIC POPULATIONS

Pediatric Use
  • Safety and effectiveness of Arixtra in pediatric patients have not been established. Because risk for bleeding during treatment with Arixtra is increased in adults who weigh <50 kg, bleeding may be a particular safety concern for use of Arixtra in the pediatric population.